Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Acquired Diseases
  • Published:

Novel gene therapy for rheumatoid arthritis by FADD gene transfer: induction of apoptosis of rheumatoid synoviocytes but not chondrocytes

Gene Therapy volume 7, pages 527–533 (2000)Cite this article

Abstract

Synovial cells in the rheumatoid synovium show abnormal proliferation, leading to joint destruction. Rheumatoid synovial cells express functional Fas antigen and are susceptible to Fas-mediated apoptosis. We have proposed the induction of apoptosis by Fas/Fas ligand system of proliferative rheumatoid synovium as a novel therapy for rheumatoid arthritis (RA). We have recently reported that Fas-associated death domain protein (FADD) plays a key role in Fas-mediated apoptosis of synovial cells in patients with RA. In this study, we determined whether FADD gene transfer could induce apoptosis of RA synoviocytes in vitro and in vivo. Transfection of FADD gene by adenoviral vector into cultured RA synoviocytes induced up-regulation of FADD expression and apoptosis. In addition, local injection of FADD adenovirus (Ad-FADD) eliminated synoviocytes in vivo by induction of apoptosis of proliferating human rheumatoid synovium engrafted in severe combined immunodeficiency mouse, which is the most suitable animal model of RA for the evaluation of treatment strategy in vivo. In addition, Ad-FADD-induced apoptosis was limited to cells of the synovium tissue and did not affect chondrocytes. Our results strongly suggest that FADD gene transfer can induce apoptosis of RA synoviocytes both in vitro and in vivo, suggesting that FADD gene transfer might be effective in the treatment of RA.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Harris ED Jr . Rheumatoid arthritis. Pathophysiology and implications for therapy New Engl J Med 1990 322: 1277–1289

    Article  Google Scholar 

  2. Weinblatt ME . Treatment of rheumatoid arthritis, In: Koopman WJ (ed) Arthritis and Allied Conditions: a Textbook of Rheumatology Williams & Wilkins: Baltimore 1997 pp 1131–1141

    Google Scholar 

  3. Nishioka K et al. Apoptosis in rheumatoid arthritis: a novel pathway in the regulation of synovial tissue Arthritis Rheum 1998 41: 1–9

    Article  CAS  Google Scholar 

  4. O'Sullivan JB, Cathcart ES . The prevalence of rheumatoid arthritis: follow-up evaluation of the effect of criteria on rates in Sudbury, Massachusetts Ann Intern Med 1972 76: 573–577

    Article  CAS  Google Scholar 

  5. Feigenbaum SL, Masi AT, Kaplan SB . Prognosis in rheumatoid arthritis: a longitudinal study of newly diagnosed younger adult patients Am J Med 1979 66: 377–384

    Article  CAS  Google Scholar 

  6. Nakajima T et al. Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes Arthritis Rheum 1995 38: 485–491

    Article  CAS  Google Scholar 

  7. Asahara H et al. Expression of Fas antigen and Fas ligand in the rheumatoid synovial tissue Clin Immunol Immunopathol 1996 81: 27–34

    Article  CAS  Google Scholar 

  8. Firestein GS, Yeo M, Zvaifler NJ . Apoptosis in rheumatoid arthritis synovium J Clin Invest 1995 96: 1631–1638

    Article  CAS  Google Scholar 

  9. Fujisawa K et al. Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-I tax transgenic mice J Clin Invest 1996 98: 271–278

    Article  CAS  Google Scholar 

  10. Okamoto K et al. Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer Gene Therapy 1998 5: 331–338

    Article  CAS  Google Scholar 

  11. Mulligan RC . The basic science of gene therapy Science 1993 260: 926–932

    Article  CAS  Google Scholar 

  12. Kondo S et al. FADD gene therapy for malignant gliomas in vitro and in vivo Hum Gene Ther 1998 9: 1599–1608

    Article  CAS  Google Scholar 

  13. Shinoura N et al. Apoptosis by retrovirus- and adenovirus-mediated gene transfer of Fas ligand to glioma cells: implications for gene therapy Hum Gene Ther 1998 9: 1983–1993

    Article  CAS  Google Scholar 

  14. Okamoto K et al. FADD is Fas-mediated apoptosis modulator in synoviocytes Rheumatology (in press)

  15. Nita I et al. Direct gene delivery to synovium. An evaluation of potential vectors in vitro and in vivo Arthritis Rheum 1996 39: 820–828

    Article  CAS  Google Scholar 

  16. Roessler BJ et al. Adenoviral-mediated gene transfer to rabbit synovium in vivo J Clin Invest 1993 92: 1085–1092

    Article  CAS  Google Scholar 

  17. Sakai K et al. Potential withdrawal of rheumatoid synovium by the induction of apoptosis using a novel in vivo model of rheumatoid arthritis Arthritis Rheum 1998 41: 1251–1257

    Article  CAS  Google Scholar 

  18. Boldin MP et al. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain J Biol Chem 1995 270: 7795–7798

    Article  CAS  Google Scholar 

  19. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM . FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis Cell 1995 81: 505–512

    Article  CAS  Google Scholar 

  20. Boldin MP, Goncharov TM, Goltsev YV, Wallach D . Involvement of MACH, a novel MORT-1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death Cell 1996 85: 803–815

    Article  CAS  Google Scholar 

  21. Muzio M et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex Cell 1996 85: 817–827

    Article  CAS  Google Scholar 

  22. Evans CH et al. Gene therapy for rheumatic diseases Arthritis Rheum 1999 42: 1–16

    Article  CAS  Google Scholar 

  23. Bandara G et al. Intraarticular expression of biologically active interleukin 1-receptor- antagonist protein by ex vivo gene transfer Proc Natl Acad Sci USA 1993 90: 10764–10768

    Article  CAS  Google Scholar 

  24. Le CH, Nicolson AG, Morales A, Sewell KL . Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor a receptor gene Arthritis Rheum 1997 40: 1662–1669

    Article  CAS  Google Scholar 

  25. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy Proc Natl Acad Sci USA 1994 91: 4407–4411

    Article  CAS  Google Scholar 

  26. Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression Proc Natl Acad Sci USA 1995 92: 1401–1405

    Article  CAS  Google Scholar 

  27. Fujisawa K et al. Activation of transcription factor NF-κB in human synovial cells in response to tumor necrosis factor α Arthritis Rheum 1996 39: 197–203

    Article  CAS  Google Scholar 

  28. Yoshida Y, Hamada H . Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal Biochem Biophys Res Commun 1997 230: 426–430

    Article  CAS  Google Scholar 

  29. Miyake S et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-treatment protein complex and a cosmid bearing the full-length virus genome Proc Natl Acad Sci USA 1996 93: 1320–1324

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Dr Toshifumi Takakuwa for preparation of paraffin sections, and Miss Hideko Morita for technical assistance. This work was supported by grants from the Ministry of Education, Science, Sports and Culture of Japan, and the Ministry and Welfare of Japan, and Rheumatology and Genetic Research Found from Santen Pharmaceutical Co. Ltd.

Author information

Authors and Affiliations

  1. Rheumatology, Immunology, and Genetics Program, Institute of Medical Science, St Marianna University School of Medicine, Kawasaki, Japan

    T Kobayashi, K Okamoto, T Kobata, T Hasunuma, T Kato & K Nishioka

  2. Division of Immunology, Institute for Medical Science, Dokkyo University School of Medicine, Tochigi, Japan

    T Kobata

  3. Department of Molecular Biotherapy Research, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan

    H Hamada

Authors
  1. T Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Kobata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Hasunuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Hamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Nishioka
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kobayashi, T., Okamoto, K., Kobata, T. et al. Novel gene therapy for rheumatoid arthritis by FADD gene transfer: induction of apoptosis of rheumatoid synoviocytes but not chondrocytes. Gene Ther 7, 527–533 (2000). https://doi.org/10.1038/sj.gt.3301127

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301127

Keywords

This article is cited by

Search

Advanced search

Quick links